Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Nov 2, 2010

165_ip_2010-11-02_015c6745-2fcb-4868-bd81-346e10bb9431.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

3rd Quarter / Nine Months Results 2010

Analysts Meeting, November 2, 2010

Forward-looking Statements

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

1. Business Update

2. Financials & Outlook

3. Questions & Answers

Excellent quarter and fully on track for full-year targets

Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
t
h
r
o
w
R
e
e
n
e
v
u		 \$
2
8
8
9
m
,		 \$
3
0
5
8
m
,		 %
6
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a		 \$
5
2
2
m		 \$
2
4
8
m		 1
0
%
i
E
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
7
6		 \$
0
8
2		 %
9
  • •Strong revenue growth at 7% at constant currency and 6% organic
  • •Very good EBIT-margin development
  • •Resulting in net income growth of 10%

Total revenue increased by 7%cc to \$3,058 m

9M Revenue

Total revenue increased by 8%cc to \$8,886 m

Page 6

Q3 Dialysis Services Global

Continued excellent revenue growth of 9%cc

\$
S
U
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
t
h
r
o
w		 c
c
i
N
h
A
t
o
r
m
e
r
c
a		 1
7
4
1
,		 1
8
6
3
,		 %
7
i
I
l
t
t
n
e
r
n
a
o
n
a		 4
0
6		 4
5
8		 %
1
3		 %
1
7
T
l
t
o
a		 2
1
4
7
,		 2
3
2
1
,		 8
%		 9
%
  • •Very good organic treatment growth of 4.7% globally
  • •Continued strong revenue per treatment development
  • •Treating 210,191 patients in 2,716 clinics

cc = constant currency

9M Dialysis Services Global

Excellent revenue growth globally

\$
S
U
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
t
h
r
o
w		 c
c
i
N
h
A
t
o
r
m
e
r
c
a		 4
9
9
5
,		 5
4
4
1
,		 %
9
I
i
l
t
t
n
e
r
n
a
o
n
a		 1
1
2
9
,		 1
2
5
7
,		 1
3
%		 1
2
%
T
l
t
o
a		 6
1
2
4
,		 6
7
1
6
,		 1
0
%		 9
%
  • •Good organic treatment growth of 4.4% globally
  • •Continued strong revenue per treatment development

cc = constant currency

Continued improvement of patient outcomes

N
t
h
A
o
r
m		 (
S
)
i
U
e
r
c
a		 E
M		 E
A
%
f
i
t
t
o
p
a
e
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9		 Q
3
2
0
1
0
K
/
V
1
2
t
≥		 9
6
%		 9
6
%		 9
5
%		 9
5
%
H
l
b
i
1
0
1
2
/
d
l
e
m
o
g
o
n
=
g
-		 6
4
%		 6
9
%		 3
%
5		 5
4
%
/
H
l
b
i
1
0
1
3
d
l
e
m
o
g
o
n
g
=
-		 %
8
7		 8
8
%		 %
7
6		 7
6
%
A
l
b
i
3
5
/
d
l
≥
m
n
g
u		 8
2
%		 8
2
%		 8
7
%		 8
6
%
/
P
h
h
t
3
5
5
5
d
l
o
s
p
a
e
m
g
-		 %
5
4		 5
7
%		 6
0
%		 6
1
%
H
i
l
i
i
d
t
t
o
s
p
a
z
a
o
n
a
y
s		 1
0
0		 *
9
8		 8
7		 9
4

The hospitalization rates for the US reflects adoption of CMS policy *

Q3 Dialysis Services Global

Further improved performance in all key metrics

Q
3
2
0
1
0		 T
l
t
o
a		 N
h
A
i
t
o
r
m
e
r
c
a		 I
i
l
t
t
n
e
r
n
a
o
n
a
O
i
t
h
r
g
a
n
c
r
e
v
e
n
u
e
g
r
o
w		 %
7		 %
7		 6
%
S
k
t
t
t
t
t
h
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 %
4
7		 %
4
3		 %
5
6
R
t
t
t
e
v
e
n
u
e
p
e
r
r
e
a
m
e
n		 *
\$
3
5
1		 \$
1
6
5
c
c
S
b
3
0,
2
0
1
0
t
e
p
e
m
e
r
f
N
b
l
i
i
m
e
r
o
c
n
c
s
u		 2
7
1
6
,		 1
8
0
9
,		 9
0
7
G
t
h
r
o
w		 %
8		 %
3		 %
1
9
D
e
n
o
v
o
s		 2
7		 4
2		 3
0

* including Mexico

Q3 Revenue per treatment US

Stable reimbursement environment

Q3 Dialysis Products

Product growth in North America impacted by mix shift

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
e
n
e
v
u
(
inc
l.
in
ter
l re
)
na
ve
nu
e		 1
0
0
3
,		 1
0
1
8
,		 %
2		 %
4
E
l
t
x
e
r
n
a
r
e
v
e
n
u
e		 7
4
2		 3
7
7		 1
%
-		 3
%
N
t
h
A
i
o
r
m
e
r
c
a		 2
0
9		 2
0
8		 %
0
I
i
l
t
t
n
e
r
n
a
o
n
a		 3
3
5		 5
2
9		 1
%
-		 4
%

cc = constant currency

Total revenue growth year to date on target

\$
S
U
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
v
e
n
u
e
(
)
inc
l.
in
ter
l re
na
ve
nu
e		 2
8
1
6
,		 2
9
8
0
,		 %
6		 %
5
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 2
0
8
8
,		 2
1
0
7
,		 %
4		 %
3
N
t
h
A
i
o
r
m
e
r
c
a		 6
0
5		 6
1
7		 2
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 1
4
8
3
,		 5
5
1
3
,		 %
5		 4
%

cc = constant currency

Q3 I 9M Summary

Product Launches

2. Financials & Outlook

Q3 Profit & Loss

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 2
8
8
9
,		 5
3
0
8
,		 *
6
%
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 4
5
1		 4
9
3		 %
9
%
E
B
I
T
i
i
m
a
r
g
n
n		 1
5
6		 1
6
1
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e,
n
e		 7
5		 0
7
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 3
7
6		 4
2
3		 %
1
2
I
t
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 1
3
1		 1
5
3
T
t
a
x
r
a
e		 3
5
%		 3
6
%
N
l
l
i
i
t
t
t
o
n-
c
o
n
r
o
n
g
n
e
r
e
s		 2
0		 2
2
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a		 2
2
5		 2
4
8		 1
0
%

* 7% growth at constant currency, 6% organic growth

9M Profit & Loss

\$
U
S
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
t
h
r
o
w
N
t
e
r
e
v
e
n
u
e		 8
2
1
2
,		 8
8
8
6
,		 *
8
%
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 1
2
6
5
,		 5
1
3
8
,		 1
0
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
5
4		 1
5
6
I
t
t
t
n
e
r
e
s
e
p
e
n
s
e,
n
e
x		 2
2
5		 2
0
6
f
I
b
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 1
0
4
0
,		 1
1
7
9
,		 1
3
%
I
t
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 3
4
5		 4
1
0
T
t
a
x
r
a
e		 3
3
%		 3
%
5
N
t
l
l
i
i
t
t
o
n-
c
o
n
r
o
n
g
n
e
r
e
s		 5
0		 6
2
N
i
t
e
n
c
o
m
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a		 6
4
5		 7
0
7		 1
0
%

* 8% growth at constant currency, 6% organic growth

Operating Margin Development

Days Sales Outstanding (DSO)

Continued excellent cash collection

Very Strong operating cash flow performance

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w
1)
O
f
t
i
h
l
p
e
r
a
n
g
c
a
s
o
w		 4
4
3		 3
8
4
1
3
%
f r
o
ev
en
ue		 1
3
%
-
1)
C
i
l
d
i
t
t
a
p
a
e
p
e
n
r
e
s
t
x
u
n
e
,		 (
)
1
3
9		 (
)
1
2
1
f
F
h
l
r
e
e
c
a
s
o
w		 3
0
4		 2
6
3
9
%
f r
o
ev
en
ue		 1
4
%
-
1)
A
i
i
i
t
f
t
d
i
t
i
t
c
q
u
s
o
n
s
n
e
o
v
e
s
u
r
e
s
,		 (
2
6
)		 (
)
8
7
1)
F
h
f
l
f
i
i
i
r
e
e
c
a
s
o
t
t
w
a
e
r
a
c
q
u
s
o
n
s
,		 2
8
7		 1
6
7

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

Operating cash flow above \$ 1 billion and at 12% of revenue

\$
S
U
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
h
t
r
o
w
1)
O
i
h
f
l
t
p
e
r
a
n
g
c
a
s
o
w		 8
8
0		 1
0
2
7
,
1
2
%
f r
o
ev
en
ue		 1
7
%
1)
C
i
t
l
d
i
t
t
a
p
a
e
x
p
e
n
u
r
e
s
n
e
,		 (
3
8
8
)		 (
)
3
3
9
f
F
h
l
r
e
e
c
a
s
o
w		 4
9
2		 6
8
8
8
%
f r
o
ev
en
ue		 4
0
%
1)
2)
A
i
i
i
t
f
d
i
i
c
q
s
o
n
s
t
t
t
u
n
e
o
v
e
s
u
r
e
s
,		 (
1
0
7
)		 (
)
2
3
9
1)
2)
f
F
h
l
f
i
i
i
r
e
e
c
a
s
o
w
t
t
a
e
r
a
c
q
u
s
o
n
s
,		 3
8
5		 4
4
9

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$131 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009

Q3 Debt and EBITDA Development

Debt/EBITDA ratio improved further

* including non-cash charges and in 2007 excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2010 GUIDANCE – Outlook improved

Fully on track for 2010 Targets

\$
U
S
i
l
l
i
m
o
n
s		 i
G
d
u
a
n
c
e
N
t
e
r
e
e
n
e
v
u		 \$
1
2
0
0
0
>
,
N
t
i
i
d
e
n
c
o
m
e
m
p
r
o
v
e
t
tr
i
bu
ta
b
le
to
F
M
C
A
G
&
Co
K
Ga
A
a		 \$
9
6
0
9
8
0
-
L
t
i
e
v
e
r
a
g
e
r
a
o
(
D
b
t
/
E
B
I
T
D
A
)
e		 2
5
<
C
i
l
d
i
t
t
a
p
a
e
x
p
e
n
u
r
e
s		 \$
0
6
0
5
5
5
-
A
i
i
i
t
c
q
s
o
n
s
u		 \$
5
0
0
t
u
p
o

3. Questions & Answers

Thank you for your interest in Fresenius Medical Care

Attachment I

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

All figures are in \$ millions

D
b
t
e		 Q
3
2
0
1
0		 F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7
S
ho
bo
ing
(
inc
l.
A
/
R
)
t-
te
r
rm
rro
w
s
p
ro
g
ra
m		 6
2
3		 3
1
6		 6
8
4		 2
1
7
S
ho
bo
ing
fro
la
d p
ies
t-
ter
te
t
+
r
m
rro
w
s
m
re
ar		 1
0		 1
0		 1 2
Cu
t p
t
ion
f
lon
ter
de
b
t a
d c
i
ta
l
lea
b
l
ig
t
ion
+
rre
n
or
o
g-
m
n
ap
se
o
a
s		 1
5
8		 1
5
8		 4
5
5		 8
5
Cu
f
fer
t p
t
ion
tru
t p
d s
i
t
ies
+
rre
n
or
o
s
re
re
ec
ur		 6
3
4		 6
0
7
Lo
-te
de
b
t a
d c
i
ta
l
lea
b
l
ig
t
ion
+
ng
rm
n
ap
se
o
a
s,
les
ion
t p
t
s c
urr
en
or		 4,
3
1
1		 4,
4
2
8		 3,
9
5
7		 4,
0
0
4
Tr
fer
d s
i
ies
t p
t
+
us
re
re
ec
ur		 - 6
6
5		 6
4
1		 6
6
4
To
l
de
b
ta
t
=		 3
6
5,
7		 6
8
5,
5		 3
8
5,
7		 6
4
2
5,
E
B
I
T
D
A		 Q
3
2
0
1
0		 1)
F
Y
2
0
0
9		 F
Y
2
0
0
8		 F
Y
2
0
0
7
La
lve
hs
ing
inc
(
E
B
I
T
)
t
tw
t
t
s
e
m
on
o
p
er
a
om
e		 1,
8
7
6		 1,
6
9
7		 1,
6
7
2		 1,
5
8
0
La
lve
hs
de
ia
ion
d a
iza
ion
t
tw
t
t
t
t
+
s
e
m
on
p
rec
an
mo
r		 4
9
2		 4
4
3		 4
1
6		 3
6
3
No
h c
ha
+
n-c
as
rg
es		 8
4		 8
4		 4
4		 1
4
E
B
I
T
D
A
(
l
ize
d
)
an
nu
a
=		 2,
4
1
6		 2,
1
8
8		 2,
1
3
2		 1,
9
8
4
C
i
l
d
i
(
)
t
t
t
a
p
a
e
x
p
e
n
u
r
e
n
e		 9
M
2
0
1
0		 9
M
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9
Pu
ha
f p
lan
d e
ip
ty,
t a
t
rc
se
o
ro
p
er
p
n
q
u
me
n		 (
3
5
0
)		 (
3
9
8
)		 (
1
2
3
)		 (
1
4
5
)
Pr
ds
fro
le
f p
lan
d e
ip
ty,
t a
t
oc
ee
m
sa
o
ro
p
er
p
n
q
me
n
u
-		 1
1		 1
0		 2 6
Ca
i
l e
d
i
(
)
ta
tu
t
p
xp
en
re
ne
=		 (
3
3
9
)		 (
3
8
8
)		 (
1
2
1
)		 (
1
3
9
)

1) Excluding restructuring costs and in-process R&D

Attachment II

Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

E
l
R
t
x
e
r
n
a
e
v
e
n
u
e

All figures are in \$ millions

(
)
A
i
i
i
t
t
c
q
s
o
n
s
n
e
u		 9
M
2
0
1
0		 9
M
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9
Ac
is
i
t
ion
d
inv
tm
t a
d
t p
ha
f
in
ta
i
b
le
ts
q
u
s a
n
es
en
n
ne
ur
c
se
s o
ng
as
se		 (
3
7
8
)		 (
1
0
9
)		 (
8
8
)		 (
2
7
)
fro
Pr
ds
d
ive
t
i
tu
oc
ee
m
s
re
s		 8 2
5		 1 1
Ac
is
i
ion
d
inv
f
d
ive
i
t
tm
ts
t o
t
tu
q
s a
n
es
en
ne
s
re
s
u
,		 (
3
0
)
7		 (
)
5
7		 (
8
)
7		 (
2
6
)
Inv
f r
tm
t,
t o
ts
es
en
ne
ep
ay
me
n		 1
3
1		 (
5
0
)		 - -
Ac
is
i
ion
f
d
ive
i
t
t o
t
tu
q
s,
ne
s
re
s
u		 (
2
3
9
)		 (
1
0
7
)		 (
8
7
)		 (
2
6
)

cc = constant currency

9
M
2
0
0
9		 9
M
2
0
1
0		 G
t
h
r
o
w
R
e
e
n
e
v
u		 \$
8
2
1
2
m
,		 \$
8
8
8
6
m
,		 %
8
N
i
t
e
n
c
o
m
e
C
G
&
Co
Ga
t
tr
i
bu
ta
b
le
to
F
M
A
K
A
a		 \$
5
6
4
m		 \$
7
0
7
m		 1
0
%
i
E
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
2
1
6		 \$
2
3
5		 %
9
  • •Strong revenue growth at 8% at constant currency and 6% organic
  • •Continued excellent cash flow development

Dialysis Services - Global

Q
3
2
0
1
0		 C
l
i
i
n
c
s		 P
i
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
ion
)
m
s
T
t
l
o
a		 2
7
1
6
,		 2
1
0
1
9
1
,		 2
3
4
G
t
h
r
o
w		 %
8
+		 %
9
+		 %
7
+
N
t
h
A
i
o
r
m
e
r
c
a		 1
8
0
9
,		 1
3
6
5
7
4
,		 1
5
5
G
h
t
r
o
w		 3
%
+		 4
%
+		 %
5
+
I
i
l
t
t
n
e
r
n
a
o
n
a		 9
0
7		 7
4
4
4
5
,		 7
9
G
t
h
r
o
w		 %
1
9
+		 %
2
0
+		 %
1
1
+
E
u
r
o
p
e		 4
8
2		 3
6,
8
7
1		 4
0
L
t
i
A
i
a
n
m
e
r
c
a		 1
9
1		 2
1,
9
3
4		 2
5
A
i
P
i
f
i
s
a-
a
c
c		 2
3
4		 1
5,
6
4
0		 1.
4

9M 2010 Operating Margin Development

Calendar & Contacts

F
Y
2
0
1
0
R
l
t
e
s
u
s		 – i
A
l
M
F
b
2
3,
2
0
1
1
t
t
n
a
y
s
e
e
n
g
e
r
u
a
r
y
,
Q
R
l
1
2
0
1
1
t
e
s
s
u		 – C
f
C
l
l,
M
4,
2
0
1
1
o
n
e
r
e
n
c
e
a
a
y
Q
2
2
0
1
1
R
l
t
e
s
u
s		 – C
f
C
l
l,
A
3,
2
0
1
1
t
o
n
e
r
e
n
c
e
a
u
g
u
s
Q
3
2
0
1
1
R
l
t
e
s
u
s		 – C
f
C
l
l,
N
b
2,
2
0
1
1
o
n
e
r
e
n
c
e
a
o
v
e
m
e
r

Fresenius Medical Care AG & Co. KGaA(Frankfurt FME / NYSE FMS) Investor RelationsElse-Kröner-Str. 161352 Bad Homburg v.d.H.

Oliver MaierHead of Investor Relations & Corp. Comm. Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 E-mail: [email protected]

Gerrit Jost

Tel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 E-mail: [email protected]

Terry L. Morris

Tel.: +1-800-948-2538Fax.: +1-615-345-5605E-mail: [email protected]

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.